Fintech

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

Globenewswire·March 30, 2026 at 11:30 AM

Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by...

Original Source

Globenewswire — www.globenewswire.com

Related in Fintech

NY Fed: Mobile Sports Betting Increases Credit Delinquency
PYMNTS
Labor Department Eases 401(k) Alternative Investment Access
PYMNTS
US rule may open trillions in 401(k) to crypto
CoinDesk
Businesses Adapt AI Budgeting to Usage-Based Pricing
PYMNTS

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

NY Fed: Mobile Sports Betting Increases Credit Delinquency

Labor Department Eases 401(k) Alternative Investment Access

US rule may open trillions in 401(k) to crypto

Businesses Adapt AI Budgeting to Usage-Based Pricing